Norwood, MA (PRWEB) November 06, 2013
BioPharm Insight’s Respiratory Disease Report covers key drugs in development in this competitive therapeutic sector. The report is based on primary research and interviews conducted with numerous physicians, investigators and key opinion leaders at the recent European Respiratory Society Annual Congress 2013 in Barcelona, Spain.
In discussing the Respiratory Disease Report, Kirsty Barnes, Biopharm Insight’s Editor EMEA, said, “The report is another example of why decision makers in pharmaceutical R&D or the investment side of drug development rely on BioPharm Insight’s independent investigative journalism, market analytics and key industry contacts to gain competitive insight.”
Some highlights and key takeaways from the report:
Subscribers to BioPharm Insight received the Respiratory Report on October 15.
Non-subscribers, download the report.
About BioPharm Insight
BioPharm Insight is part of Infinata, a Financial Times Group company, and a leading provider of business intelligence solutions which also include BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com.
About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.
Business Inquiries: Holly Burke, hburke[at]infinata[dot]com, 781-619-0131
Media Inquiries: Brenda Nashawaty, Brenda[at]nashawaty[dot]com, 617-688-3253
Read the full story at http://www.prweb.com/releases/2013/11/prweb11300052.htm.
Copyright©2012 Vocus, Inc.
All rights reserved